Full Press Release Details
argenx announces publication of efgartigimod Phase 2 primary immune thrombocytopenia trial results in American Journal of Hematology.
ARGX
argenx announces publication of efgartigimod Phase 2 primary immune thrombocytopenia trial results in American Journal of Hematology
Key Takeaway: argenx announces publication of efgartigimod Phase 2 primary immune thrombocytopenia trial results in American Journal of Hematology